
Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Swiss Noema Pharma raises CHF54m in Series A financing
It is one of the largest Series A rounds in Europe: Led by Sofinnova Partners and Polaris Partners, rare neurological diseases start-up Noema Pharma...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

EU approves second COVID-19 vaccine
The EU has secured a total of 160 million doses of mRNA-1273 from the US-American manufacturer Moderna, which has outsourced production sites on the...

Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Cancer antibody specialist BioInvent International AB has granted the exclusive rights to market its anti-FcγRIIB antibody, BI-1206, in China,...

Atriva Therapeutics gets €24m from EIB
According to Atriva Therapeutics, the proceeds allow the company to start Phase II testing of its oral MEK inhibitor ATR-002. In preclinical trails,...

LSP leads €21m round into Neurent Medical
Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...